[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659535":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":33,"interventions":46,"overallOfficials":66,"centralContacts":70,"locations":76,"responsibleParty":92,"collaborators":94,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":21,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":21,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":21,"overallStatus":120,"whyStopped":21,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Dual task gait speed cost","This cost will be operationalized as the absolute and percent change in gait metrics (time to walk\u002Fvariability) during dual-task walking relative to walking without a secondary task. Cost will be defined as (\\[speed dual task - speed single task\\]\u002Fspeed single task\\] \\*100). Will fit a series of linear mixed models with each of the dual task costs, prefrontal cortex activation, and executive function measures as the dependent variables; sequence, period, and treatment as fixed effects of interest; baseline values as fixed effect covariates; and a participant-within sequence random effect.","Before and after stimulation at visit 2 and 3",[14,18],{"measure":15,"description":16,"timeFrame":17},"Dual task cost to gait speed","Will fit a series of analyses of covariance models with each gait single task and dual-task cost measure as the dependent variable; group (older, taxane-treated female breast cancer survivors versus non-cancer historical control group) as the factor of interest; and other measures of interest (age, proprioception, grip strength, depression, and pain) or other variables different between groups as covariates.","At baseline",{"measure":19,"description":20,"timeFrame":17},"Prefrontal hemodynamic response","Assessed via functional near-infrared spectroscopy during dual task gait speed. Will fit a series of linear mixed models with each measure of prefrontal cortex activation as the dependent variable; group (older, taxane-treated female breast cancer survivors versus non-cancer historical control group), task (single\u002Fdual), and their interaction as fixed effects; covariates as additional fixed effects; and a participant random effect.",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":25,"primaryPurpose":26,"observationalModel":21,"timePerspective":21,"maskingInfo":27},"RANDOMIZED","CROSSOVER","Patients are randomized to 1 of 2 arms. After completing the intervention from their original arm they cross over to the remaining arm.","SUPPORTIVE_CARE",{"masking":28,"maskingDescription":29,"whoMasked":30},"DOUBLE","This method will effectively blind participants and study personnel to group assignment.",[31,32],"PARTICIPANT","CARE_PROVIDER",[34,42],{"label":35,"type":36,"description":37,"interventionNames":38},"Arm I: tDCS first, followed by sham","EXPERIMENTAL","Patients receive tDCS, over 20 minutes. One week later patients crossover to receive sham",[39,40,41],"Procedure: Sham Intervention","Other: Survey Administration","Device: Transcranial Direct Current Stimulation",{"label":43,"type":36,"description":44,"interventionNames":45},"Arm II (sham tDCS followed by tDCS)","Patients receive sham tDCS, over 20 minutes. One week later patients crossover to receive treatment with actual tDCS",[39,40,41],[47,55,59],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"PROCEDURE","Sham Intervention","Receive sham tDCS",[35,43],[53,54],"sham (procedure)","Sham Comparator",{"type":6,"name":56,"description":57,"armGroupLabels":58,"otherNames":21},"Survey Administration","Ancillary studies",[35,43],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":64},"DEVICE","Transcranial Direct Current Stimulation","Receive tDCS",[35,43],[65],"tDCS",[67],{"name":68,"affiliation":5,"role":69},"Brendan L McNeish","PRINCIPAL_INVESTIGATOR",[71],{"name":72,"role":73,"phone":74,"phoneExt":21,"email":75},"Eshaka Eshwar","CONTACT","734-232-5901","eshaka@med.umich.edu",[77],{"facility":5,"status":21,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Ann Arbor","Michigan","48109","United States","US",{"type":84,"coordinates":85},"Point",[86,87],-83.74088,42.27756,{"lat":87,"lon":86},[90],{"name":91,"role":69,"phone":21,"phoneExt":21,"email":21},"Brendan L. McNeish",{"type":93,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[95],{"name":96,"class":97},"National Institute on Aging (NIA)","NIH","100659535","transcranial-direct-current-stimulation-to-improve-gait-for-breast-cancer-survivors-who-received-taxene-andor-platinum-chemotherapy-100659535",false,"NCT07864792","Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and\u002For Platinum Chemotherapy","A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of the Impact of Transcranial Direct Current to the Left Dorsolateral Prefrontal Cortex on Gait in Older Breast Cancer Survivor's Post-Taxane Chemotherapy","Inclusion Criteria:\n\n* Women aged 60-85 years\n* Breast cancer survivors, stages I-IV without clinical suspicion or evidence of brain metastasis\n* Completion of last taxane and\u002For platinum chemotherapy treatment ≥ 6 months prior, but chemotherapy was received after the age of 60. Taxane combined with a history of platinum, anthracycline and\u002For cyclophosphamide is permitted. Active anti-estrogen therapy, Anti-HER2, and CDK 4\u002F6 inhibitors are permitted\n* Ability to walk unassisted for 60 seconds\n* Proficient in English\n* Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD)\n* No history of a second cancer besides skin cancer\n\nExclusion Criteria:\n\n* Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance\n* Any unstable medical condition\n* Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder\n* Chronic vertigo\n* Myocardial infarction within the past six months\n* History of immune check point inhibitor therapy\n* Any history of brain or cervical spine surgery, known hearing, visual, or vestibular impairment\n* Active neurotoxic chemotherapy (taxane, platinum or vinca alkaloid) or radiation therapy\n* Contraindications to transcranial direct simulation (tDCS), including reported seizure within the past two years,, metal objects in head or neck, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp","FEMALE","60 Years","85 Years",{"count":109,"type":110},60,"ESTIMATED","INTERVENTIONAL",[113],"NA","This clinical trial tests the effect of transcranial direct current stimulation (tDCS) to improve gait in older breast cancer survivors who received taxane and\u002For platinum chemotherapy. Chemotherapy, especially taxane or platinum therapy, can cause damage to the to the nerves resulting in numbness, tingling and pain, which can cause difficulty walking. It can also cause cognitive dysfunction which may effect gait. TDCS is a non-invasive brain stimulation device which uses a very mild electrical current applied to the scalp to temporarily stimulate a specific area of the brain involved in thinking and movement which may improve walking, particularly while doing two things at once. TDCS may be effective in improving gait for older breast cancer survivors who received taxane and\u002For platinum chemotherapy.",[116,117,118,119],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","NOT_YET_RECRUITING","2026-10-02",{"date":123,"type":124},"2026-10-08","ACTUAL",{"date":126,"type":110},"2026-09",{"date":128,"type":110},"2029-09",{"name":5,"class":6},1]